Comparative Pharmacology
Head-to-head clinical analysis: SULFOSE versus SULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFOSE versus SULLA.
SULFOSE vs SULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamide antibiotic; inhibits bacterial dihydropteroate synthase, blocking folate synthesis and bacterial growth.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
Meningococcal meningitis: 100 mg/kg/day intravenously in 4 divided doses (maximum 6 g/day). For other infections: 2-4 g/day IV/IM in 3-4 divided doses.
100 mg orally once daily, increased to 200 mg daily if needed.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in patients with normal renal function; prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
6-12 hours; prolonged in renal impairment (up to 30 hours)
Renal: ~90% as unchanged drug via glomerular filtration; biliary/fecal: <10%.
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic